Table 1 Baseline characteristics of population and univariate analysis of patients with KPC-Kp BSI by survival status
Characteristic | All patients N = 102 | Patients who survived N= 56 | Patients who did not survive N= 46 | p value |
|---|---|---|---|---|
Age, years, median (IQR) | 64 (53–74) | 55 (41.5–70.75) | 70.5 (60–77.25) | < 0.001 |
Male sex | 65 (63.7%) | 39 (69.6%) | 26 (56.5%) | 0.170 |
Comorbidities | ||||
Diabetes | 18 (17.6%) | 5 (8.9%) | 13 (28.3%) | 0.011 |
Cardiovascular disease | 36 (35.3%) | 11 (19.6%) | 25 (54.3%) | < 0.001 |
Chronic renal disease | 15 (14.7%) | 6 (10.7%) | 9 (19.6%) | 0.209 |
Chronic liver disease | 13 (12.7%) | 9 (16.1%) | 4 (8.7%) | 0.266 |
COPD | 10 (9.8%) | 2 (3.6%) | 8 (17.4%) | 0.020 |
Solid cancer | 27 (26.5%) | 13 (23.2%) | 14 (30.4%) | 0.411 |
Hematological malignancy | 14 (13.7%) | 8 (14.3%) | 6 (13%) | 0.856 |
Solid organ transplantation | 8 (7.8%) | 5 (8.9%) | 3 (6.5%) | 0.653 |
Previous hospitalization | 40 (39.2%) | 21 (37.5%) | 19 (41.3%) | 0.695 |
Previous antibiotic therapy | 58 (56.9%) | 35 (62.5%) | 23 (50%) | 0.205 |
Length of ICU stay after KPC-Kp BSI, days, median (IQR) | 18 (9–28.5) | 24 (15.75–44.75) | 12 (5–18) | < 0.001 |
ICU stay, days, median (IQR) | 39 (21–59) | 44.5 (29.75–75.5) | 27 (15.5–50.75) | < 0.001 |
Hospital length of stay before bacteremia, days, median (IQR) | 17.5 (5.75–36.5) | 18.5 (7–34.25) | 13 (3.75–39) | 0.362 |
Primary cause of ICU admission | 16 (15.7%) | 8 (14.3%) | 8 (17.4%) | 0.668 |
Trauma | 16 (15.7%) | 11 (19.6%) | 5 (10.9%) | 0.225 |
Respiratory failure | 16 (15.7%) | 12 (21.4%) | 4 (8.7%) | 0.078 |
Cardiovascular disease | 15 (14.7%) | 6 (10.7%) | 9 (19.6%) | 0.209 |
Surgery | 13 (12.7%) | 7 (12.5%) | 6 (13%) | 0.935 |
Infection | 11 (10.8%) | 6 (10.7%) | 5 (10.9%) | 0.980 |
Burn injury | 10 (9.8%) | 3 (5.4%) | 7 (15.2%) | 0.096 |
Cerebrovascular accident | 5 (4.9%) | 3 (5.4%) | 2 (4.3%) | 0.814 |
Other* | ||||
Source of infection | ||||
CVC-related bacteremia | 13 (12.7%) | 11 (19.6%) | 2 (4.3%) | 0.021 |
Primary bacteremia | 14 (13.7%) | 2 (3.6%) | 12 (26.1%) | 0.001 |
Respiratory tract | 11 (10.8%) | 6 (10.7%) | 5 (10.9%) | 0.980 |
Urinary tract | 21 (20.6%) | 12 (21.4%) | 9 (19.6%) | 0.817 |
Skin and skin structure | 18 (17.6%) | 13 (23.2%) | 5 (10.9%) | 0.104 |
Intra-abdominal | 24 (23.5%) | 12 (21.4%) | 12 (26.1%) | 0.581 |
Endocarditis | 1 (0.9%) | 0 | 1 (2.2%) | 0.268 |
Type of acquisition | ||||
Healthcare-associated | 13 (12.7%) | 3 (5.4%) | 10 (21.7%) | 0.014 |
Nosocomial | 89 (87.2%) | 53 (94.6%) | 36 (78.3%) | 0.014 |
Charlson Comorbidity Index, median (IQR) | 2 (1–3) | 2 (0–3) | 2 (1.75–3.25) | 0.078 |
KPC-Kp intestinal colonization | 52 (51%) | 31 (55.4%) | 21 (45.7%) | 0.329 |
Source control | 65 (63.7%) | 40 (81.6%) | 25 (80.6%) | 0.912 |
Septic shock | 40 (39.2%) | 18 (32.1%) | 22 (47.8%) | 0.106 |
Mechanical ventilation | 40 (39.2%) | 23 (41.1%) | 17 (37%) | 0.672 |
AKI | 15 (14.7%) | 8 (14.3%) | 7 (15.2%) | 0.895 |
SOFA score, median (IQR) | 5 (3–9.5) | 4 (2–10) | 7.5 (4–9.25) | 0.034 |
APACHE II score, median (IQR) | 15 (11–21) | 13.5 (10–20) | 19 (12–21) | 0.040 |
DNR | 3 (2.9%) | 1 (1.8%) | 2 (4.3%) | 0.446 |
Time from blood culture collection to appropriate antibiotic therapy, hours, median (IQR) | 15 (1–60) | 8.5 (1–36) | 48 (5–108) | 0.014 |